Alzheimer’s drug spurs some hope

For the first time, researchers are reporting that a treatment might help stabilize Alzheimer’s disease for as much as three years, although the evidence is weak and in only four patients. The drug is Gammagard, made by Baxter International Inc. Doctors say that four patients who have been receiving the highest dose for three years showed no decline on memory and cognition tests. A dozen others on different doses or shorter treatment times didn’t fare as well.

For the first time, researchers are reporting that a treatment might help stabilize Alzheimer’s disease for as much as three years, although the evidence is weak and in only four patients.

The drug is Gammagard, made by Baxter International Inc. Doctors say that four patients who have been receiving the highest dose for three years showed no decline on memory and cognition tests. A dozen others on different doses or shorter treatment times didn’t fare as well.

This study was far too small to prove the treatment works, but a more rigorous one involving 400 patients will give results within a year.

Still, the findings from the small study encouraged doctors at the Alzheimer’s Association International Conference in Vancouver, British Columbia, where they were presented on Tuesday.

“It’s tantalizing. If you were to pick out four people with Alzheimer’s disease, the likelihood that they would perform the same on standardized tests three years later is very, very tiny,” said William Thies, the association’s scientific director.

People typically go from diagnosis to death in about eight years, so to be stable for three years “is a long time,” he said. “We shouldn’t get euphoric and we shouldn’t get unreasonable enthusiasm, but this is a positive piece of data.”

The need for an effective treatment is huge: About 35 million people worldwide have dementia, and Alzheimer’s is the most common type. In the U.S., about five million have Alzheimer’s. Current medicines such as Aricept and Namenda just temporarily ease symptoms. There is no known cure.

Gammagard is intravenous immune globulin, or IVIG — multiple, natural antibodies culled from donated blood. Half a dozen companies already sell IVIG to treat immune system and blood disorders. These antibodies may help remove amyloid, the sticky plaque that clogs patients’ brains, sapping memory and ability to think.

On Tuesday, Dr. Norman Relkin, head of a memory disorders program at New York-Presbyterian Hospital/Weill Cornell Medical Center, gave three-year follow-up results on 16 of 24 patients in an earlier study of Gammagard aimed at finding the right dose to use in the larger study. The other eight are no longer being followed, and at least some of them have died.

After the early study ended, some participants were kept on Gammagard and some who had been receiving dummy infusions were switched to Gammagard.

Relkin found:

l As a group, the 11 patients started on various doses of Gammagard fared better than the five started on dummy infusions.

l The five given dummy treatments declined more slowly after they were switched to Gammagard.

l All four participants originally given the highest dose and kept on that dose for three years showed no decline in cognition.

“To have all four not progress was very eye-opening,” Relkin said. Even a single patient who doesn’t decline over three years is unusual, he said.

“When I see that in clinical practice, I start to question whether the person has Alzheimer’s disease,” but all of these study participants were verified by advanced testing to have it, he said.

Jason Marder is among them. The New York City man, who turned 70 last week, was diagnosed with Alzheimer’s more than eight years ago and continues to get Gammagard infusions every two weeks from a visiting nurse at home. “I feel that I haven’t gone down, and that’s good,” he said in a recent interview. “I feel good. I’m very independent.”

His wife, Karin Marder, said: “He has slowed down, no question about it. His walk is a little slower but that could also have a lot to do with age. He’s still the Jason that I married. He’s still there. We still have a wonderful relationship together. I’m grateful for every day that he’s independent.”

Other doctors warned against over-optimism on these early results. Many previous drugs looked good until tested in large, definitive studies.

“That’s the only way we can get data we can really rely on,” said Dr. Reisa Sperling, a neurologist at Harvard-affiliated Brigham and Women’s Hospital in Boston.

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

Don't Look Down Tattoo hosted a flash tattoo event on Friday afternoon. (Twila Amato - Black Press Media)
Albertans can make hair and tattoo appointments today as some COVID restrictions ease

EDMONTON — Albertans will be able to visit hair salons and tattoo… Continue reading

A blood donor clinic pictured at a shopping mall in Calgary, Friday, March 27, 2020. THE CANADIAN PRESS/Jeff McIntosh
Blood donors needed

Canada Life Week to Save Lives campaign

Premier Jason Kenney condemns Joe Biden’s plan to scrap the Keystone XL pipeline expansion, in a Jan. 18, 2021 story. (Photo by Paul Taillon/Office of the Premier)
Kenney, Moe condemn Biden’s plan to scrap Keystone XL on Day 1 of presidency

Kenney prepared to ‘use all legal avenues available’

A member of staff at the university hospital injects the Moderna vaccine against COVID-19 into a patient in Duesseldorf, Monday, Jan. 18, 2021. (Federico Gambarini/dpa via AP)
WHO chief lambasts vaccine profits, demands elderly go first

One poor country received a mere 25 vaccine doses

Dwayne Buckle, 40 of Red Deer finished a 1,638-kilometre walk, in honour of his family. The 12-week, 82 day-journey wrapped up in Port Hardy, B.C. on Monday. Facebook photo
Red Deer man completes 1,638 km hike for cancer research

Dwayne Buckle, a Red Deer firefighter returned home Friday after his 12-week journey

Pipes intended for the Keystone XL project are show in a yard in Gascoyne, N.D., on Wednesday April 22, 2015. THE CANADIAN PRESS/Alex Panetta
TC Energy plans net zero emissions for Keystone XL even as project’s future in doubt

CALGARY — Cancelling TC Energy Corp.’s Keystone XL pipeline expansion project would… Continue reading

Conservative Leader Erin O’Toole holds a press conference on Parliament Hill, in Ottawa on December 10, 2020. THE CANADIAN PRESS/Sean Kilpatrick
No place for ‘far right’ in Conservative Party, Erin O’Toole says

OTTAWA — Federal Conservative Leader Erin O’Toole pushed back against attempts to… Continue reading

Facebook/ The Open Door 24/7 Integrated Response Hub- Wetaskiwin.
Wetaskiwin residents show support for 24/7 Integrated Response Hub

Wetaskiwin residents and City Council members showed support for Hub with positive signs.

Indonesian soldiers distribute relief goods for those affected by the earthquake at a stadium in Mamuju, West Sulawesi, Indonesia, Sunday, Jan. 17, 2021. Rescuers retrieved more bodies from the rubble of homes and buildings toppled by the 6.2 magnitude earthquake while military engineers managed to reopen ruptured roads to clear access for aid relief goods. (AP Photo/Daeng Mansur)
Aid effort intensifies after Indonesia quake that killed 84

Nearly 20,000 were survivors moved to shelters and more than 900 people were injured

Deeply covered with snow are the trees at the Grenzadler in Oberhof, Germany, Sunday, Jan. 17, 2021. Two World Cups are taking place in the town on the Rennsteig this weekend. In front of empty crowds, the best lugers and biathletes compete for World Cup points. (Martin Schutt/dpa via AP)
Freezing weather hits much of Europe, from Poland to Turkey

A skier in Switzerland died after buried by an avalanche on the weekend

Canada forward Cyle Larin, left, vies for the ball with Mexico defender Nestor Araujo during the second half of a CONCACAF Gold Cup soccer match Wednesday, June 19, 2019, at Mile High Stadium in Denver. THE CANADIAN PRESS/AP, David Zalubowski
Canadian forward Cyle Larin plays provider in Besiktas win over Istanbul rival

Larin into the game having scored six times in his previous three outings

Skip Brendan Bottcher celebrates his victory over Team Koe in the men’s final of the Humpty’s Champions Cup in Saskatoon, Sask., on April 28, 2019. THE CANADIAN PRESS/Matt Smith
Curling Alberta decision will have ripple effect on potential wild-card teams

National federation adds two more wild-card teams to the field at Scotties Tournament of Hearts and Tim Hortons Brier

Most Read